Provention Bio Inc

NASDAQ:PRVB  
4.08
+0.18 (+4.62%)
Earnings Announcements

Provention Bio Reports First Quarter 2022 Financial Results

Published: 05/05/2022 12:53 GMT
Provention Bio Inc (PRVB) - Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update.
Provention Bio - Teplizumab Biologics License Application Resubmission Accepted for Review by FDA and User Fee Goal Date Set for August 17, 2022.
Qtrly Loss per Share of $0.35.
Expects Its Cash-based Operating Expenses to Be in Range of $29.0 Million to $33.0 Million for Q2 of 2022.
Provention Bio - Believes Cash, Cash Equivalents & Marketable Securities As of March 31, 2022, Are Sufficient to Fund Co's Operations Into Q1 of 2023.
Q1 Earnings per Share View $-0.47 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.73 Million
Adjusted EPS is expected to be -$0.50

Next Quarter Revenue Guidance is expected to be $0.83 Million
Next Quarter EPS Guidance is expected to be -$0.72

More details on our Analysts Page.